Clinical Trials Logo

Inflammatory Bowel Diseases clinical trials

View clinical trials related to Inflammatory Bowel Diseases.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04456400 Suspended - Ulcerative Colitis Clinical Trials

Enhancing Ultrasound & Photoacoustic for Recognition of Intestinal Abnormalities

EUPHORIA
Start date: February 3, 2021
Phase:
Study type: Observational

The clinical investigation aims to generate clinical data to support the use of Multispectral Optoacoustic Tomography (MSOT) in clinical practice, its inclusion in diagnostic guidelines and to support its reimbursement, specifically to - Further validate the application with respect to including ulcerative colitis patients - Prepare a study protocol for large-scale clinical validation study in inflammatory bowel disease (IBD) - Successfully execute the clinical validation study

NCT ID: NCT04306939 Suspended - Clinical trials for Rheumatoid Arthritis

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

GREAT1
Start date: November 1, 2014
Phase:
Study type: Observational

This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect clinical decision making. The study will evaluate risk factors and co-variants, including genetic variants that are associated with disease progression such as pain, inflammation, organ dysfunction, disability and quality of life.

NCT ID: NCT04225819 Suspended - Ulcerative Colitis Clinical Trials

Adjunctive Treatment With Vitamin D3 in Patients With Active IBD

ACTIVATED
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Inflammatory bowel disease ((IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC)), is a chronic, immune-mediated disease characterized by recurrent episodes of relapse. The incidence of IBD is increasing worldwide and poses as a burden that reduces quality of life and has a significant impact on health care resources. The advent of monoclonal antibodies to tumor necrosis factor-α (anti-TNF) has revolutionized treatment of IBD, improving rates of remission and reducing hospitalizations and surgeries. Nevertheless, many patients do not adequately respond to these therapies or lose response over time. Thus, there is an important need for novel immunomodulating agents to improve our ability to achieve remission. Besides its traditional role in bone homeostasis, several studies have recognized the important role Vitamin D plays in modulating the immune response, cancer, and cardiovascular disease. Specifically, Vitamin D may mediate immunity by modulating autophagy in leukocytes and regulating the gut microbiome. Thus, Vitamin D may play an important role in IBD. Furthermore, evidence suggests that the effect of vitamin D may be mediated through the TNF-α pathway, suggesting a synergy with anti-TNF therapy. This is a randomized, double blind, placebo-controlled trial to study the effect of Vitamin D3 as an adjunct therapy for patients with active CD, UC, or IBD unspecified who are undergoing anti-TNF induction therapy.

NCT ID: NCT04205734 Suspended - IBD Clinical Trials

Methotrexate Polyglutamate Measurements in Patients With Inflammatory Bowel Disease

Start date: January 30, 2021
Phase:
Study type: Observational

There are currently no serum levels to help guide appropriate methotrexate therapy. Data from this study will assess the correlation between dosing and whole blood methotrexate(MTX) polyglutamate measurements in children and adolescents with IBD.

NCT ID: NCT04143490 Suspended - Ulcerative Colitis Clinical Trials

Effects of Exercise in Patients With Ulcerative Colitis

Start date: November 4, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effects of moderate to high intensity exercise on gut function and inflammatory markers in patients with Ulcerative Colitis (UC), and to compare them with individuals of matched age who do not suffer from Inflammatory Bowel Disease. Participants will be asked to complete 60 minutes of continuous cycling at a moderate to high intensity followed by a three hour recovery period. Gastrointestinal function will be measured using a non-invasive breath test. Blood samples will be collected at multiple time-points during the visit and these samples will be measured for markers of immune function and intestinal integrity.